** Shares of Artrya fall as much 9% to A$0.455, their lowest level since Oct 23
** The medical technology co receives firm commitments to raise A$5 mln ($3.29 mln) via placement
** Issue price of A$0.42 represents 16% discount to co's last close on Thursday, Nov. 7
** Adds, fund raised to be allocated to product development, others, as co awaits FDA clearance on its patented Salix Coronary Anatomy product
** Stock up 95.8% this year, including session's moves
($1 = 1.5221 Australian dollars)
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。